Sean Tan
@Stempoint Capital Lp
Latest period2024 - Q3ReportedManaged Assets$334.017MTotal holdings50
Assets growth rate-1.84%Assets growth rate (2-Q avg)-5.94%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Stempoint Capital Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 50 positions.
Assets under management
The assets under management (AUM) of Stempoint Capital Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 334.017M in assets, with a quarterly growth rate of -1.84% and a 2-quarter average growth rate of -5.94%. The portfolio is managed by Sean Tan, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ACLXArcellx Inc
| 1.51% | $5.017M 60,076 shares@ $83.52 avg price | Decreased -78.59% |
VTGNVistagen Therapeutics Inc
| 1.47% | $4.901M 1.847M shares@ $2.66 avg price | Decreased -0.09% |
NRIXNurix Therapeutics Inc
| 1.37% | $4.562M 203,015 shares@ $22.47 avg price | Decreased -0.12% |
TCRXTscan Therapeutics Inc
| 1.29% | $4.288M 860,951 shares@ $4.99 avg price | Increased 1.88% |
ZURAZura Bio Ltd
| 1.27% | $4.239M 1.044M shares@ $4.06 avg price | New Position |
IDYAIdeaya Biosciences Inc
| 1.26% | $4.204M 132,703 shares@ $31.68 avg price | Increased 30.38% |
TERNTerns Pharmaceuticals Inc
| 1.13% | $3.747M 449,321 shares@ $8.34 avg price | New Position |
CATXPerspective Therapeutics Inc
| 0.96% | $3.178M 238,084 shares@ $13.35 avg price | Decreased -30.75% |
PYXSPyxis Oncology Inc
| 0.94% | $3.12M 850,210 shares@ $3.68 avg price | Decreased -29.3% |
NGNENeurogene Inc
| 0.93% | $3.076M 73,299 shares@ $41.96 avg price | Decreased -6.74% |